Nothing Special   »   [go: up one dir, main page]

PL2234645T3 - Preparaty interferonu-beta modyfikowanego PEG - Google Patents

Preparaty interferonu-beta modyfikowanego PEG

Info

Publication number
PL2234645T3
PL2234645T3 PL08863833T PL08863833T PL2234645T3 PL 2234645 T3 PL2234645 T3 PL 2234645T3 PL 08863833 T PL08863833 T PL 08863833T PL 08863833 T PL08863833 T PL 08863833T PL 2234645 T3 PL2234645 T3 PL 2234645T3
Authority
PL
Poland
Prior art keywords
peg
interferon
surfactant
buffer
beta formulations
Prior art date
Application number
PL08863833T
Other languages
English (en)
Inventor
Rio Alessandra Del
Joel Richard
Original Assignee
Merck Serono Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Serono Sa filed Critical Merck Serono Sa
Publication of PL2234645T3 publication Critical patent/PL2234645T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
PL08863833T 2007-12-20 2008-12-18 Preparaty interferonu-beta modyfikowanego PEG PL2234645T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP07150258 2007-12-20
US1025808P 2008-01-07 2008-01-07
PCT/EP2008/067876 WO2009080699A2 (en) 2007-12-20 2008-12-18 Peg-interferon-beta formulations
EP08863833A EP2234645B1 (en) 2007-12-20 2008-12-18 Peg-interferon-beta formulations

Publications (1)

Publication Number Publication Date
PL2234645T3 true PL2234645T3 (pl) 2012-10-31

Family

ID=39760852

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08863833T PL2234645T3 (pl) 2007-12-20 2008-12-18 Preparaty interferonu-beta modyfikowanego PEG

Country Status (20)

Country Link
US (1) US9138403B2 (pl)
EP (1) EP2234645B1 (pl)
JP (2) JP5563475B2 (pl)
KR (1) KR20100099298A (pl)
CN (1) CN101878043A (pl)
AT (1) ATE555812T1 (pl)
AU (1) AU2008340058A1 (pl)
BR (1) BRPI0821029A2 (pl)
CY (1) CY1112820T1 (pl)
DK (1) DK2234645T3 (pl)
EA (1) EA201070773A1 (pl)
ES (1) ES2387236T3 (pl)
HR (1) HRP20120483T1 (pl)
IL (1) IL206441A0 (pl)
PL (1) PL2234645T3 (pl)
PT (1) PT2234645E (pl)
RS (1) RS52417B (pl)
SI (1) SI2234645T1 (pl)
WO (1) WO2009080699A2 (pl)
ZA (1) ZA201001908B (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2387236T3 (es) * 2007-12-20 2012-09-18 Merck Serono S.A. Formulaciones de interferón beta pegilado
US20120269770A1 (en) * 2010-11-22 2012-10-25 Mark Brader Stable Preserved Compositions of Interferon-Beta
RU2015143521A (ru) * 2013-03-13 2017-04-19 Илэвэн Байотерапьютикс, Инк. Лекарственные формы химерных цитокинов для глазной доставки
JPWO2016052584A1 (ja) * 2014-09-30 2017-07-13 東レ株式会社 ポリエチレングリコール修飾インターフェロン−βの検出及び定量に使用する試料液の前処理方法、ポリエチレングリコール修飾インターフェロン−βの検出方法及び定量方法
CN107206089A (zh) * 2014-11-10 2017-09-26 葛兰素史克知识产权第二有限公司 用于丙型肝炎的联合长效组合物和方法
WO2016163764A2 (ko) * 2015-04-07 2016-10-13 에이비온 주식회사 인터페론 베타 변이체의 안정화 제제
KR101943160B1 (ko) * 2016-10-06 2019-01-30 에이비온 주식회사 인터페론 베타 변이체의 안정화 제제
CN116023466B (zh) * 2023-03-30 2023-06-27 北京生物制品研究所有限责任公司 纯化PEG修饰重组人干扰素β1b蛋白的方法

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
EP0098110B1 (en) 1982-06-24 1989-10-18 NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD Long-acting composition
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4588585A (en) 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4432895A (en) 1982-11-24 1984-02-21 Hoffmann-La Roche Inc. Monomeric interferons
US4469228A (en) 1983-05-31 1984-09-04 Schering Corporation Interferon kit
US4636383A (en) 1984-08-29 1987-01-13 Schering Corporation Interferon-cyclaradine combination
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US5116943A (en) 1985-01-18 1992-05-26 Cetus Corporation Oxidation-resistant muteins of Il-2 and other protein
US5017691A (en) 1986-07-03 1991-05-21 Schering Corporation Mammalian interleukin-4
US4879111A (en) 1986-04-17 1989-11-07 Cetus Corporation Treatment of infections with lymphokines
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4904584A (en) 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US5997856A (en) 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
IT1244511B (it) 1991-04-15 1994-07-15 Isi Ist Sierovaccinogeno Ital Idrogeli a base di policarbossilati sintetici e proteine per il rilascio controllato di farmaci e procedimento per la loro preparazione.
KR950014915B1 (ko) 1991-06-19 1995-12-18 주식회사녹십자 탈시알로당단백-포함화합물
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
IT1272252B (it) 1994-05-16 1997-06-16 Applied Research Systems Formulazioni liquide di interferone beta
JP2758154B2 (ja) 1995-04-06 1998-05-28 エフ・ホフマン−ラ ロシユ アーゲー インターフェロンを含む液体製剤
US5656730A (en) 1995-04-07 1997-08-12 Enzon, Inc. Stabilized monomeric protein compositions
US5814485A (en) 1995-06-06 1998-09-29 Chiron Corporation Production of interferon-β (IFN-β) in E. coli
US5858001A (en) 1995-12-11 1999-01-12 Elan Medical Technologies Limited Cartridge-based drug delivery device
ATE203157T1 (de) 1996-12-20 2001-08-15 Alza Corp Injizierbare depotgelzubereitung und herstellungsverfahren
EE04223B1 (et) 1996-12-24 2004-02-16 Biogen, Incorporated Interferooni stabiilne vedelkompositsioon, mis sisaldab aminohappeid
US6013253A (en) 1997-08-15 2000-01-11 Amgen, Inc. Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist
DE59805732D1 (de) 1997-09-23 2002-10-31 Rentschler Biotech Gmbh Flüssige interferon-beta-formulierungen
IL136326A0 (en) 1997-12-08 2001-05-20 Genentech Inc Human interferon-epsilon: a type i interferon
WO1999048535A1 (en) 1998-03-26 1999-09-30 Schering Corporation Formulations for protection of peg-interferon alpha conjugates
ATE275422T1 (de) * 1998-04-28 2004-09-15 Applied Research Systems Konjugate aus polyole und beta-interferon
EP1656952B1 (en) 1998-10-16 2013-12-18 Biogen Idec MA Inc. Polyalkylene glycol conjugates of interferon beta-1A and uses thereof
US6143314A (en) 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
US7754855B1 (en) 1999-07-13 2010-07-13 Bolder Biotechnology, Inc. Immunoglobulin fusion proteins
US6531122B1 (en) 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
CN1175901C (zh) 1999-12-06 2004-11-17 天津华立达生物工程有限公司 一种稳定的干扰素水溶液
US6465425B1 (en) 2000-02-10 2002-10-15 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins
WO2002003472A2 (en) 2000-06-29 2002-01-10 California Institute Of Technology Aerosol silicon nanoparticles for use in semiconductor device fabrication
KR100396983B1 (ko) 2000-07-29 2003-09-02 이강춘 고반응성의 가지 달린 고분자 유도체 및 고분자와 단백질또는 펩타이드의 접합체
AU2002219198B2 (en) 2000-12-27 2006-06-29 Ares Trading S.A. Lipid microparticles by cryogenic micronization
US6887462B2 (en) 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
JP2004522803A (ja) * 2001-06-29 2004-07-29 マキシゲン・エイピーエス インターフェロン製剤
US20040028733A1 (en) 2002-02-08 2004-02-12 Alkermes Controlled Therapeutics, Inc. Polymer-based compositions for sustained release
AU2002357557A1 (en) 2002-05-14 2003-11-11 Beijing Jiankai Technology Co. Ltd. Targeted hydrophilic polymer, binders with interferon and medical composite comprising above binders
US20040037809A1 (en) 2002-06-28 2004-02-26 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of interferon beta
MXPA05000658A (es) * 2002-07-17 2005-08-19 Biogen Idec Inc Terapias para la insuficiencia renal utilizando interferon-beta.
US20060151574A1 (en) 2002-11-29 2006-07-13 Gpc Biotech Ag Formulations useful against hepatitis C virus infections
ES2389183T3 (es) 2002-12-26 2012-10-23 Mountain View Pharmaceuticals, Inc. Conjugados de polietilenglicol de interferón-beta-1b con potencia biológica in vitro potenciada
TWI272948B (en) * 2003-05-01 2007-02-11 Ares Trading Sa HSA-free stabilized interferon liquid formulations
BRPI0411166A (pt) * 2003-05-12 2006-07-18 Affymax Inc composto compreendendo uma parcela de peptìdeo, uma parcela espaçadora e uma parcela de polìmero solúvel em água e composição farmacêutica compreendendo tal composto
AR044302A1 (es) 2003-05-13 2005-09-07 Ares Trading Sa Formulaciones con proteinas liquidas estabilizadas en recipientes farmaceuticos
JP4850514B2 (ja) * 2003-08-25 2012-01-11 東レ株式会社 インターフェロンβ複合体
AU2004298781B2 (en) 2003-12-11 2010-04-01 Ares Trading S.A. Stabilized interferon liquid formulations
JP2007526317A (ja) * 2004-03-01 2007-09-13 エンゾン ファーマスーティカルズ インコーポレイテッド インターフェロン−ベータ・ポリマー結合体
CA2566364A1 (en) 2004-05-17 2005-11-24 Ares Trading S.A. Hydrogel interferon formulations
EA010979B1 (ru) 2004-06-01 2008-12-30 Арес Трейдинг С.А. Стабилизированные жидкие препаративные формы интерферона
WO2005117948A1 (en) 2004-06-01 2005-12-15 Ares Trading S.A. Method of stabilizing proteins
DE602005022895D1 (de) * 2004-08-12 2010-09-23 Schering Corp Stabile pegylierte interferon-formulierung
ES2387236T3 (es) * 2007-12-20 2012-09-18 Merck Serono S.A. Formulaciones de interferón beta pegilado

Also Published As

Publication number Publication date
DK2234645T3 (da) 2012-07-09
SI2234645T1 (sl) 2012-07-31
WO2009080699A2 (en) 2009-07-02
ATE555812T1 (de) 2012-05-15
CY1112820T1 (el) 2016-02-10
PT2234645E (pt) 2012-05-21
HRP20120483T1 (hr) 2012-07-31
JP2011506562A (ja) 2011-03-03
WO2009080699A3 (en) 2009-11-26
RS52417B (en) 2013-02-28
US9138403B2 (en) 2015-09-22
EP2234645B1 (en) 2012-05-02
ES2387236T3 (es) 2012-09-18
KR20100099298A (ko) 2010-09-10
AU2008340058A1 (en) 2009-07-02
EP2234645A2 (en) 2010-10-06
EA201070773A1 (ru) 2010-12-30
JP5563475B2 (ja) 2014-07-30
BRPI0821029A2 (pt) 2015-06-16
IL206441A0 (en) 2010-12-30
CN101878043A (zh) 2010-11-03
US20100239529A1 (en) 2010-09-23
ZA201001908B (en) 2011-05-25
JP2014159445A (ja) 2014-09-04

Similar Documents

Publication Publication Date Title
IL206441A0 (en) Peg-interferon-beta formulations and their preparation
NZ600096A (en) Formulations of antibody
IL180380A (en) Pharmaceuticals containing botulinum toxin or botulinum toxin to high purity level and surfactant as a stabilizer
AU2009215514A9 (en) Composition comprising a combination of omeprazole and lansoprazole, and a buffering agent, and methods of using same
MX2010009850A (es) Analogos de insulina acilados y etabilizados contra proteasas.
ZA200809864B (en) Pharmaceutical formulations for the sustained release of active ingredients(s), as well as their applications, especially therapeutic
WO2007109812A3 (en) Immunopotentiating compounds
WO2008008364A3 (en) Enhanced stability phenylephrine liquid compositions
IL193274A0 (en) Pharmaceutical formulation for aerosols, comprising two or more active agents and at least one surfactant
UA90875C2 (ru) Лекарственные формы пролонгированного действия, которые содержат ранолазин
EP1909825A4 (en) STABILIZED PARATHYROID HORMONE COMPOSITION COMPRISING A PARATHYROID HORMONE, A STAMP AND A STABILIZING AGENT
MX2012003951A (es) Preparacion farmceutica que comprende hcg recombinante.
EP1708719A4 (en) AQUEOUS PHARMACEUTICAL COMPOSITIONS OF 2,6-DIISOPROPYLPHENOL (PROPOFOL) AND THEIR USE
MX2010005589A (es) Composicion para el cuidado personal.
UA94032C2 (ru) Жидкая стабализированная композиция интерферона без hsa
DE502007005902D1 (de) -methyl-19-nor-20- spirox-4-en-3-one), sowie diese enthaltende pharmazeutische präparate
MY153391A (en) Composition for controlling parasites on animals
NO20070187L (no) Oralt desintegrerende farmasoytisk preparat omfattende risperidon
GB0417367D0 (en) Pharmaceutical composition containing botulinum neurotoxin
GB0423952D0 (en) Pharmaceutical composition containing botulinum neurotoxin
UA93540C2 (ru) Фармацевтическая композиция для аэрозольного распыления c двумя действующими веществами и, по меньшей mepe, одним поверхностно-активным веществом
SI2176282T1 (sl) 8-beta-substituirani 16 alfa-fluoro-estratrieni kot selektivno aktivni estrogenic
GB0423953D0 (en) Pharmaceutical composition containing botulinum neurotoxin
WO2009087175A3 (en) Allergy vaccine composition for mucosal administration
GB0421288D0 (en) Pharmaceutical composition containing botulinum neurotoxin